(TRAW)
NCM – Real vaqt narxi. Valyuta: USD
1.76
-0.17 (-8.81%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
1.75
-0.01 (-0.57%)
Bozordan keyin: Mar 27, 2026, 7:23 PM EDT

NCM – Real vaqt narxi. Valyuta: USD
1.76
-0.17 (-8.81%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
1.75
-0.01 (-0.57%)
Bozordan keyin: Mar 27, 2026, 7:23 PM EDT
Traws Pharma, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, respirator virusli kasalliklar va saraton uchun og'iz orqali qabul qilinadigan kichik molekulali mahsulot nomzodlarini ishlab chiqadi. Kompaniya gripp va COVID-19 uchun tadqiqot ostidagi yangi dorilarni ishlab chiqmoqda, ular davolashga chidamliligini bartaraf etish uchun ishlab chiqilgan, masalan, COVID-19ni davolash uchun ishlab chiqilayotgan ingibitor TRX01 (Ratutrelvir); va qush grippi va mavsumiy grippni davolash uchun ishlab chiqilayotgan endonukleaz ingibitori bo'lgan Tivoxavir marboxil. Shuningdek, u qattiq o'smalar va gematologik malignansiyalarda birinchi darajali vosita sifatida yoki boshqa saratonga qarshi dorilar bilan birgalikda qo'llaniladigan ko'p maqsadli kinaz ingibitori bo'lgan narazatsiklibni; va turli xil saraton turlarini tadqiq qilish uchun yolg'iz yoki birgalikda yuboriladigan rigosertibni ishlab chiqmoqda. Muz SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc. va Temple University bilan litsenzion shartnomalarga ega. Kompaniya ilgari Onconova Therapeutics, Inc. nomi bilan tanilgan va 2024 yil aprel oyida Traws Pharma, Inc. nomini olgan. Traws Pharma, Inc. 1998 yilda ro'yxatga olingan va shtab-kvartirasi Nyu-taun, Pensilvaniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Charles David Pauza Ph.D. | Chief Scientific Officer of Virology |
| Dr. Iain D. Dukes DPHIL, M.A., Ph.D. | CEO, Secretary & Director |
| Dr. Nikolay Savchuk Ph.D. | COO & Director |
| Dr. Robert R. Redfield M.D. | Chief Medical Officer |
| Dr. Victor Moyo M.D. | Chief Medical Officer of Oncology |
| Mr. Charles Parker | Chief Financial Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-01-26 | 8-K | tm264027d1_8k.htm |
| 2026-01-13 | 8-K | tm263039d1_8k.htm |
| 2025-12-17 | 8-K | tm2533729d1_8k.htm |
| 2025-12-16 | 8-K | tm2533625d1_8k.htm |
| 2025-11-28 | 8-K | tm2532319d1_8k.htm |
| 2025-11-13 | 8-K | tm2531045d1_8k.htm |
| 2025-10-17 | 8-K | tm2528641d1_8k.htm |
| 2025-10-14 | 8-K | tm2528641d2_8k.htm |
| 2025-10-08 | DEF 14A | tm2527912-1_def14a.htm |
| 2025-10-06 | 8-K | tm2528048d1_8k.htm |